1-(but-2-ynyl)-2-(3-tert-butoxycarbonylaminopiperidin-1-yl)-5-(3-methylisoquinolin-1-ylmethylaminocarbonyl)-1H-imidazole | 872966-20-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 异喹啉及其衍生物
• 英文名称: 1-(but-2-ynyl)-2-(3-tert-butoxycarbonylaminopiperidin-1-yl)-5-(3-methylisoquinolin-1-ylmethylaminocarbonyl)-1H-imidazole
• 英文别名: tert-butyl N-[1-[1-but-2-ynyl-5-[(3-methylisoquinolin-1-yl)methylcarbamoyl]imidazol-2-yl]piperidin-3-yl]carbamate
• CAS: 872966-20-6
• 化学式: C₂₉H₃₆N₆O₃
• 分子量: 516.643
• InChiKey: JGBBYTYBACHMSW-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.2
• 重原子数：
  38
• 可旋转键数：
  8
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.45
• 拓扑面积：
  101
• 氢给体数：
  2
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  1-(but-2-ynyl)-2-(3-tert-butoxycarbonylaminopiperidin-1-yl)-5-(3-methylisoquinolin-1-ylmethylaminocarbonyl)-1H-imidazole 在 三氟乙酸 作用下， 以 二氯甲烷 为溶剂， 生成 1-(but-2-ynyl)-2-(3-amino-piperidin-1-yl)-5-(3-methyl-isoquinolin-1-ylmethylaminocarbonyl)-1H-imidazole
  参考文献：
  名称：

  3,5-Dihydro-imidazo[4,5-d]pyridazin-4-ones: A class of potent DPP-4 inhibitors

  摘要：

  Systematic variations of the xanthine scaffold in close analogs of development compound BI 1356 led to the class of 3,5-dihydro-imidazo[4,5-d]pyridazin-4-ones which provided, after substituent screening, a series of highly potent DPP-4 inhibitors. (C) 2008 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2008.04.075
• 作为产物：
  描述：

  2-(3-tert-butoxycarbonylamino-piperidin-1-yl)-3-(but-2-ynyl)-3H-imidazole-4-carboxylic acid 、 1-Aminomethyl-3-methyl-isochinolin 在 O-(benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium tetrafluoroborate 、 N,N-二异丙基乙胺 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 生成 1-(but-2-ynyl)-2-(3-tert-butoxycarbonylaminopiperidin-1-yl)-5-(3-methylisoquinolin-1-ylmethylaminocarbonyl)-1H-imidazole
  参考文献：
  名称：

  3,5-Dihydro-imidazo[4,5-d]pyridazin-4-ones: A class of potent DPP-4 inhibitors

  摘要：

  Systematic variations of the xanthine scaffold in close analogs of development compound BI 1356 led to the class of 3,5-dihydro-imidazo[4,5-d]pyridazin-4-ones which provided, after substituent screening, a series of highly potent DPP-4 inhibitors. (C) 2008 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2008.04.075

文献信息

• New imidazoles and triazoles, their preparation, and their use as pharmaceutical compositions
  申请人：Eckhardt Matthias

  公开号：US20060004074A1

  公开（公告）日：2006-01-05

  The present invention relates to imidazoles and triazoles of general formula wherein R 1 to R 4 and X are defined as in claims 1 to 8, the tautomers, the enantiomers, the diastereomers, the mixtures thereof and the salts thereof, which have valuable pharmacological properties, particularly an inhibiting effect on the activity of the enzyme dipeptidylpeptidase-IV (DPP-IV).

  本发明涉及一般式的咪唑和三唑，其中R1至R4和X的定义如权利要求1至8中所定义，其互变异构体、对映体、非对映体、它们的混合物和盐，具有有价值的药理特性，特别是对二肽基肽酶-IV（DPP-IV）酶活性的抑制作用。
• IMIDAZOLES AND TRIAZOLES, THEIR PREPARATION, AND THEIR USE AS PHARMACEUTICAL COMPOSITIONS
  申请人：ECKHARDT Matthias

  公开号：US20080312243A1

  公开（公告）日：2008-12-18

  The present invention relates to imidazoles and triazoles of general formula wherein R 1 to R 4 and X are defined as in claims 1 to 8 , the tautomers, the enantiomers, the diastereomers, the mixtures thereof and the salts thereof, which have valuable pharmacological properties, particularly an inhibiting effect on the activity of the enzyme dipeptidylpeptidase-IV (DPP-IV).

  本发明涉及通式如下的咪唑和三唑：其中R1至R4和X如权利要求1至8所定义，它们的互变异构体、对映异构体、顺反异构体、混合物和盐具有有价值的药理学特性，尤其是对二肽基肽酶-IV（DPP-IV）酶活性的抑制作用。
• US7470716B2
  申请人：——

  公开号：US7470716B2

  公开（公告）日：2008-12-30
• US7906539B2
  申请人：——

  公开号：US7906539B2

  公开（公告）日：2011-03-15
• 3,5-Dihydro-imidazo[4,5-d]pyridazin-4-ones: A class of potent DPP-4 inhibitors
  作者：Matthias Eckhardt、Norbert Hauel、Frank Himmelsbach、Elke Langkopf、Herbert Nar、Michael Mark、Moh Tadayyon、Leo Thomas、Brian Guth、Ralf Lotz

  DOI：10.1016/j.bmcl.2008.04.075

  日期：2008.6

  Systematic variations of the xanthine scaffold in close analogs of development compound BI 1356 led to the class of 3,5-dihydro-imidazo[4,5-d]pyridazin-4-ones which provided, after substituent screening, a series of highly potent DPP-4 inhibitors. (C) 2008 Elsevier Ltd. All rights reserved.